Cas no 356-12-7 (Fluocinonide)

Fluocinonide is a potent synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly formulated as a topical cream, ointment, or gel for the treatment of inflammatory skin conditions such as eczema, psoriasis, and allergic dermatitis. Its high glucocorticoid receptor affinity ensures effective reduction of erythema, swelling, and itching. Fluocinonide exhibits enhanced skin penetration due to its fluorinated structure, allowing for lower dosing frequencies compared to non-halogenated corticosteroids. It is particularly useful for resistant or severe dermatoses where moderate- to high-potency steroids are indicated. Proper application minimizes systemic absorption, reducing the risk of adverse effects. Its stability and efficacy make it a reliable option in dermatological therapeutics.
Fluocinonide structure
Fluocinonide structure
Product Name:Fluocinonide
CAS No:356-12-7
MF:C26H32F2O7
MW:494.5249
MDL:MFCD00079302
CID:37035
PubChem ID:9642
Update Time:2026-03-03

Fluocinonide Chemical and Physical Properties

Names and Identifiers

    • Fluocinonide
    • 1,4-PREGNADIEN-6-ALPHA, 9-ALPHA-DIFLUORO-11-BETA, 16-ALPHA, 17,21-TETROL-3,20-DIONE 16,17-ACETONIDE 21-ACETATE
    • FLUOCINOLONE ACETONIDE 21-ACETATE
    • FLUOCINOMIDE
    • FLUOCINONIDE ACETONIDE 21-ACETATE
    • droxy-,cyclic17-acetalwithacetone,21-acetate
    • flucinar
    • fluocinolide
    • Fluocinolone
    • Fluocinolone Acetonide Acetate
    • (6α,11β,16α)-21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
    • Lonide
    • Pregna-1,4-diene-3,20-dione,6a,9-difluoro-11b,16a,17,21-tetrahydroxy-, cyclic 16,17-acetal withacetone, 21-acetate (7CI,8CI)
    • 2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxole,pregna-1,4-diene-3,20-dione deriv.
    • Biscosal
    • Dermaplus
    • Flucetonide
    • Fluocinolide acetate
    • Lidex
    • Lidex E
    • Metosyn
    • NSC101791
    • Straderm
    • Topsym
    • Topsymin
    • Topsyn
    • Topsyne
    • Vanos
    • Fluocinolone acetonide
    • Fluonex
    • LIDEX-E
    • Lyderm
    • Fluocinonidum [INN-Latin]
    • Fluocinonide Emulsified Base
    • Fluocinonido [INN-Spanish]
    • Cortalar
    • Bestasone
    • Synalar acetate
    • Fluocinonide(Vanos)
    • Fluocinonide, micronised
    • 2W4A77YPAN
    • MLS000028476
    • Fluocinonide Cream
    • C05AA11
    • FLUOCINONIDE (MART.)
    • FLUOCINONIDE [VANDF]
    • FLUOCINOLONE ACETONIDE IMPURITY M [EP IMPURITY]
    • CAS-356-12-7
    • NCGC00022398-03
    • 1ST2244
    • BSPBio_000848
    • Opera_ID_1780
    • NS00001330
    • Fluocinonidum
    • NCGC00016436-01
    • FLUOCINONIDE (USP-RS)
    • Fluocinonide, United States Pharmacopeia (USP) Reference Standard
    • DB01047
    • HY-B0485
    • FLUOCINONIDE [WHO-DD]
    • AKOS015896516
    • Prestwick3_000774
    • Acetonide 21-Acetate, Fluocinolone
    • NSC-101791
    • HMS2097K10
    • CCG-220774
    • Fluocinolone Acetonide 21 Acetate
    • NSC 101791
    • Fluocinonida
    • 6alpha,9-Difluoro-11beta,21-dihydroxy-16alpha,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione 21-acetate
    • SR-01000003097-3
    • Prestwick0_000774
    • SR-01000003097
    • FLUOCINONIDE [USP-RS]
    • LIDEX (TN)
    • Fluocinonide (JP17/USP/INN)
    • Tox21_110438
    • Fluocinol Pak
    • Fluocinonide [USAN:BAN:INN:JAN]
    • Fluocinonidum (INN-Latin)
    • FAPG, Fluocinonide
    • Fluocinonide (USAN:USP:INN:BAN:JAN)
    • SCHEMBL4262
    • FLUOCINONIDE [USAN]
    • Vanos (TN)
    • (6alpha,11beta,16alpha)-21-(Acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione
    • FLUOCINONIDE [ORANGE BOOK]
    • UNII-2W4A77YPAN
    • AC-2071
    • Fluocinonide Topical Solution USP, 0.05%
    • BRD-K57886322-001-03-4
    • WJOHZNCJWYWUJD-IUGZLZTKSA-N
    • Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate
    • 356-12-7
    • GTPL7078
    • W-106660
    • D07AC08
    • DA-53244
    • HMS2234H04
    • Q5462791
    • BCP9000697
    • NCGC00022398-05
    • s2608
    • Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate
    • Fluocinonide (Vanos)
    • Fluocinonide FAPG
    • Tox21_110438_1
    • Fluocinonide [USAN:USP:INN:BAN:JAN]
    • NC00621
    • [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate
    • HMS3259N05
    • 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl acetate
    • Fluoxiv
    • BRD-K57886322-001-12-5
    • HMS1570K10
    • BPBio1_000934
    • 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate
    • SMR000058331
    • Prestwick2_000774
    • DTXSID8045307
    • FLUOCINONIDE [MART.]
    • MFCD00079302
    • Prestwick1_000774
    • BS-17093
    • C07007
    • Prestwick_1066
    • DTXCID6025307
    • Fluocinonide 0.1% 120gm Cream, 100% Soft Silicone Roll
    • FLUOCINONIDE [USP IMPURITY]
    • Fluocinonido (INN-Spanish)
    • HMS3714K10
    • Fluocinonide Gel
    • CHEMBL1501
    • FLUOCINONIDE [INN]
    • EINECS 206-597-6
    • D00325
    • CHEBI:5109
    • FLUOCINONIDE [MI]
    • PREGNA-1,4-DIENE-3,20-DIONE, 21-(ACETYLOXY)-6,9-DIFLUORO-11-HYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-
    • SPBio_002787
    • fluocinonide cream, silicone roll, self-adhesive wrap
    • FLUOCINONIDE (USP IMPURITY)
    • Fluocinonide, >=98% (HPLC)
    • Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
    • Fluovix Plus
    • EN300-19736975
    • Fluocinonido
    • (6ALPHA,11BETA,16ALPHA)-21-(ACETYLOXY)-6,9-DIFLUORO-11-HYDROXY-16,17-[(1-METHYLETHYLIDENE)BIS(OXY)]-PREGNA-1,4-DIENE-3,20-DIONE
    • FLUOCINONIDE [JAN]
    • MDL： MFCD00079302
    • Inchi： 1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
    • InChI Key： WJOHZNCJWYWUJD-IUGZLZTKSA-N
    • SMILES： F[C@@]12[C@]3(C([H])=C([H])C(C([H])=C3[C@]([H])(C([H])([H])[C@@]1([H])[C@]1([H])C([H])([H])[C@]3([H])[C@](C(C([H])([H])OC(C([H])([H])[H])=O)=O)([C@@]1(C([H])([H])[H])C([H])([H])[C@]2([H])O[H])OC(C([H])([H])[H])(C([H])([H])[H])O3)F)=O)C([H])([H])[H]

Computed Properties

  • Exact Mass: 494.21200
  • Monoisotopic Mass: 494.21160968g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 9
  • Heavy Atom Count: 35
  • Rotatable Bond Count: 4
  • Complexity: 1070
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 9
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 2
  • XLogP3: 3.2
  • Topological Polar Surface Area: 99.1

Experimental Properties

  • Density: 1.2001 (estimate)
  • Melting Point: 309 oC
  • Boiling Point: 591.1°C at 760 mmHg
  • Solubility: DMSO: ≥19mg/mL
  • PSA: 99.13000
  • LogP: 2.93760
  • Specific Rotation: D +83° (chloroform)

Fluocinonide Security Information

  • Signal Word：Danger
  • Hazard Statement： H300-H361
  • Warning Statement： P264-P301+P310
  • Hazardous Material transportation number：UN 2811 6.1/PG 2
  • WGK Germany：3
  • Hazard Category Code： 28-63
  • Safety Instruction： S22; S25; S28; S36/37/39; S45
  • RTECS：TU3831000
  • Hazardous Material Identification： T+
  • HazardClass：6.1(a)
  • PackingGroup：Ⅲ
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
  • Safety Term：6.1(a)
  • Risk Phrases：R28

Fluocinonide Customs Data

  • HS CODE：2937210000
  • Customs Data：

    China Customs Code:

    2937210000

Fluocinonide Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-LA063-25mg
Fluocinonide
 356-12-7 98+%
25mg
 407CNY 2021-05-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-LA063-100mg
Fluocinonide
 356-12-7 98+%
100mg
 350.0CNY 2021-07-10
MedChemExpress
HY-B0485-10mM*1mLinDMSO
Fluocinonide
 356-12-7 99.49%
10mM*1mLinDMSO
 ￥660 2023-07-26
MedChemExpress
HY-B0485-100mg
Fluocinonide
 356-12-7 99.63%
100mg
 ￥500 2025-04-16
MedChemExpress
HY-B0485-500mg
Fluocinonide
 356-12-7 99.63%
500mg
 ￥1880 2025-04-16
S e l l e c k ZHONG GUO
S2608-100mg
Fluocinonide
 356-12-7 99.75%
100mg
 ￥899.38 2023-09-16
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R023066-1g
Fluocinonide
 356-12-7 98%
1g
 ￥2100 2024-05-24
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R023066-5g
Fluocinonide
 356-12-7 98%
5g
 ￥1826 2024-05-24
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R023066-25mg
Fluocinonide
 356-12-7 98%
25mg
 ￥190 2024-05-24
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R023066-100mg
Fluocinonide
 356-12-7 98%
100mg
 ￥474 2024-05-24

Fluocinonide Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:356-12-7)Fluocinonide
Order Number:A822901
Stock Status:in Stock
Quantity:500mg
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 05:16
Price ($):194.0
Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:356-12-7)Fluocinonide
Order Number:sfd9367
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:35
Price ($):discuss personally
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:356-12-7)Fluocinonide
Order Number:LE12092;LE2806;LE26533638
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:06
Price ($):discuss personally
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
(CAS:356-12-7)Fluocinonide
Order Number:LE151
Stock Status:in Stock
Quantity:5KG/1KG/25KG/100KG
Purity:99% HPLC
Pricing Information Last Updated:Thursday, 14 August 2025 14:44
Price ($):negotiated

Fluocinonide Spectrogram

MS-MS LC-ESI-qTof
MS-MS
1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Fluocinonide Related Literature

Related Categories

Additional information on Fluocinonide

Introduction to Fluocinonide (CAS No. 356-12-7) in Modern Pharmaceutical Applications

Fluocinonide, with the chemical identifier CAS No. 356-12-7, is a synthetic corticosteroid that has garnered significant attention in the field of pharmaceuticals due to its potent anti-inflammatory and immunosuppressive properties. This compound, belonging to the class of fluorinated corticosteroids, has been widely utilized in the formulation of topical treatments for various dermatological conditions. Its high molecular weight and lipophilic nature contribute to its prolonged skin penetration, making it an effective therapeutic agent for managing chronic inflammatory disorders.

The mechanism of action of Fluocinonide revolves around its ability to bind to glucocorticoid receptors, thereby modulating gene expression and inhibiting the production of pro-inflammatory cytokines. This interaction not only reduces inflammation but also suppresses immune responses, making it particularly valuable in treating conditions characterized by excessive immune activity. Recent studies have highlighted its efficacy in managing severe cases of eczema, psoriasis, and other autoimmune dermatoses.

In clinical settings, Fluocinonide is often administered in the form of creams, ointments, and patches, which are designed to deliver the compound directly to the affected area. The prolonged release formulations have been particularly beneficial for patients requiring long-term treatment, as they minimize the frequency of application while maintaining therapeutic levels of the drug. This has been supported by pharmacokinetic studies that demonstrate sustained plasma concentrations even after multiple days of continuous use.

One of the most compelling aspects of Fluocinonide is its potential in reducing systemic side effects associated with other corticosteroids. Unlike some alternatives, which may require higher systemic doses to achieve comparable topical effects, Fluocinonide exhibits a strong local action with minimal systemic absorption. This characteristic makes it an attractive option for patients who are sensitive to systemic corticosteroid use or those who require prolonged treatment regimens.

The latest research in this domain has also explored the role of Fluocinonide in combination therapies. Studies have indicated that when used alongside other anti-inflammatory agents, such as calcineurin inhibitors or topical immunomodulators, it can enhance therapeutic outcomes. This synergistic approach not only improves patient compliance by reducing the need for multiple applications but also provides a more comprehensive management strategy for complex dermatological conditions.

Evidence from clinical trials has consistently demonstrated the efficacy of Fluocinonide in improving symptoms such as redness, itching, and scaling associated with various inflammatory skin disorders. For instance, a recent multicenter study reported a significant reduction in disease severity scores among patients treated with topical Fluocinonide compared to placebo groups. These findings reinforce its position as a cornerstone therapy in modern dermatological practice.

The safety profile of Fluocinonide has also been extensively evaluated. While localized side effects such as skin atrophy and striae formation have been reported with prolonged use, these are generally manageable with proper patient education and monitoring. Furthermore, the compound's low systemic absorption rate mitigates concerns about systemic corticosteroid-related adverse effects.

Innovations in drug delivery systems have further expanded the applications of Fluocinonide. Advanced formulations such as microspheres and nanotechnology-based carriers have been developed to enhance drug delivery efficiency and reduce local irritation. These advancements not only improve patient comfort but also optimize therapeutic response by ensuring targeted release profiles.

The future prospects for Fluocinonide are promising, with ongoing research exploring its potential beyond traditional dermatological uses. Preliminary studies suggest that it may have applications in managing inflammatory eye conditions and even certain autoimmune diseases due to its potent immunomodulatory effects. As our understanding of inflammatory pathways continues to evolve, it is likely that new therapeutic indications for this compound will emerge.

In conclusion, Fluocinonide (CAS No. 356-12-7) represents a significant advancement in the treatment of inflammatory skin disorders. Its potent anti-inflammatory properties, combined with a favorable safety profile and innovative delivery systems, make it an indispensable tool in modern dermatology. As research progresses and new applications are discovered, this compound is poised to remain at the forefront of therapeutic interventions for inflammatory conditions.

356-12-7 (Fluocinonide) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:356-12-7)Fluocinonide
A822901
Purity:99%
Quantity:500mg
Price ($):194.0
Email
Suzhou Senfeida Chemical Co., Ltd
(CAS:356-12-7)Fluocinonide
sfd9367
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email